TriNetX PSM retrospective 82,069 OCD patients, showing lower risk of COVID-19 with fluvoxamine use.
Standard of Care (SOC): SOC for COVID-19 in the study country,
the USA, is
very poor with
very low average efficacy for approved treatments
1.
Only expensive, high-profit treatments were approved. Low-cost treatments were excluded, reducing the probability of treatment—especially early—due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
|
risk of case, 28.0% lower, OR 0.72, p < 0.001, treatment 4,558, control 4,558, propensity score matching, RR approximated with OR.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Diaz et al., 6 Oct 2022, retrospective, USA, peer-reviewed, 2 authors.
DOI record:
{
"DOI": "10.4088/pcc.22br03337",
"ISSN": [
"2155-7780"
],
"URL": "http://dx.doi.org/10.4088/PCC.22br03337",
"author": [
{
"affiliation": [],
"family": "Diaz",
"given": "Ailyn D.",
"sequence": "first"
},
{
"affiliation": [],
"family": "Baweja",
"given": "Raman",
"sequence": "additional"
}
],
"container-title": "The Primary Care Companion For CNS Disorders",
"container-title-short": "Prim. Care Companion CNS Disord.",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2022,
9,
29
]
],
"date-time": "2022-09-29T21:33:32Z",
"timestamp": 1664487212000
},
"deposited": {
"date-parts": [
[
2022,
9,
29
]
],
"date-time": "2022-09-29T21:33:32Z",
"timestamp": 1664487212000
},
"indexed": {
"date-parts": [
[
2022,
9,
29
]
],
"date-time": "2022-09-29T22:11:28Z",
"timestamp": 1664489488944
},
"is-referenced-by-count": 0,
"issue": "5",
"issued": {
"date-parts": [
[
2022,
10,
6
]
]
},
"journal-issue": {
"issue": "5",
"published-online": {
"date-parts": [
[
2022,
10,
6
]
]
}
},
"member": "2558",
"original-title": [],
"prefix": "10.4088",
"published": {
"date-parts": [
[
2022,
10,
6
]
]
},
"published-online": {
"date-parts": [
[
2022,
10,
6
]
]
},
"publisher": "Physicians Postgraduate Press, Inc",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.psychiatrist.com/pcc/ocd/protective-effect-fluvoxamine-covid-19-obsessive-compulsive-disorder-real-world-case-control-study/"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"General Medicine"
],
"subtitle": [
"A Real-World Case-Control Study"
],
"title": "Protective Effect of Fluvoxamine for COVID-19 in Obsessive-Compulsive Disorder",
"type": "journal-article",
"volume": "24"
}
